FDA Approvals of 2012

2 of 39


Drug: Picato
Generic molecule: ingenol mebutate
Company: Leo Pharma
Approval date: Jan. 23

The scoop: Picato is a topical treatment for actinic keratosis (AK), a precancerous condition that can lead to squamous cell carcinoma (SCC), the second most common type of skin cancer. The topical gel treatment is completed within two or three days, compared with the weeks or even months other options require.